DeepMed Research

Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Fluorescent Lymphography-Guided Lymphadenectomy In Laparoscopic Proctectomy

Not Applicable

Conditions: Rectal Cancer

Interventions: Drug: Indocyanine Green

First Posted Date: 2019-02-26

Last Posted Date: 2019-05-14

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT03854890

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer

Phase 2

Conditions: Extensive-stage Small Cell Lung Cancer

Interventions: Drug: anlotinib

First Posted Date: 2019-02-15

Last Posted Date: 2019-03-28

Lead Sponsor: Fudan University

Target Recruit Count: 70

Registration Number: NCT03841136

Locations: 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China

Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma

Not Applicable

Conditions: Hepatocellular Carcinoma

Interventions: Drug: lenvatinib
Procedure: TACE

First Posted Date: 2019-02-12

Last Posted Date: 2022-08-02

Lead Sponsor: Fudan University

Target Recruit Count: 297

Registration Number: NCT03838796

Locations: 🇨🇳
Huashan hospital, Shanghai, China

Physical and Psychological Effects of Different Temperature-controlled Breast Prostheses on Patients With Breast Cancer

Not Applicable

Completed

Conditions: External Breast Prostheses

Interventions: Other: different temperature-controlled breast prostheses

First Posted Date: 2019-02-05

Last Posted Date: 2019-02-05

Lead Sponsor: Fudan University

Target Recruit Count: 30

Registration Number: NCT03830294

UGT1A1 Combined With Pharmacokinetics of SN-38 in CPT-11-based CRT in Patients With Advanced Rectal Cancer

Not Applicable

Conditions: Locally Advanced Rectal Cancer

Interventions: Diagnostic Test: Blood concentration check

First Posted Date: 2019-01-31

Last Posted Date: 2019-01-31

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT03824899

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia

Phase 2

Conditions: Thrombopenia
Recurrent Colorectal Carcinoma

Interventions: Drug: rhTPO
Drug: irinotecan
Drug: Raltitrexed
Radiation: radiotherapy
Drug: rhIL-11

First Posted Date: 2019-01-30

Last Posted Date: 2019-01-30

Lead Sponsor: Fudan University

Target Recruit Count: 50

Registration Number: NCT03823079

FUSCC Refractory TNBC Umbrella (FUTURE)

Phase 1

Conditions: Triple-negative Breast Cancer

Interventions: Drug: MES with anti-VEGFR included therapy
Drug: Pyrotinib with Capecitabine
Drug: AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4)
Drug: PARP inhibitor included therapy
Drug: anti PD-1 with nab-paclitaxel
Drug: BLIS with anti-VEGFR included therapy
Drug: mTOR inhibitor with nab-paclitaxel

First Posted Date: 2019-01-15

Last Posted Date: 2022-08-10

Lead Sponsor: Fudan University

Target Recruit Count: 140

Registration Number: NCT03805399

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Albumin-Bound Paclitaxel Combined With Carboplatin as Neoadjuvant Chemotherapy in Luminal B/HER-2 Negative Breast Cancer

Phase 4

Conditions: HER-2 Negative Breast Cancer

Interventions: Drug: Chemotherapy

First Posted Date: 2019-01-10

Last Posted Date: 2019-01-10

Lead Sponsor: Fudan University

Target Recruit Count: 78

Registration Number: NCT03799692

Locations: 🇨🇳
Department of Breast Surgery, Cancer Hospital, Fudan University, Shanghai, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer

Phase 4

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Chemotherapeutic Agent

First Posted Date: 2019-01-10

Last Posted Date: 2019-01-10

Lead Sponsor: Fudan University

Target Recruit Count: 60

Registration Number: NCT03799679

Locations: 🇨🇳
Cancer Hospital/ Institute, Fudan University, Shanghai, Shanghai, China

Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

Phase 2

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: Irinotecan
Drug: DDP
Drug: Endostar

First Posted Date: 2019-01-09

Last Posted Date: 2019-01-09

Lead Sponsor: Fudan University

Target Recruit Count: 76

Registration Number: NCT03797625

Locations: 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy